{"preliminary_commentary":{"by_channel":{"youtube":38,"x_thread":35,"podcast":34,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04546009\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["giredestrant","palbociclib"]],"indication":null,"name":"persevERA","nct_id":"NCT04546009","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=persevera-nct04546009. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Giredestrant + Letrozole-matched Placebo + Palbociclib","type":"EXPERIMENTAL"},{"description":null,"label":"Letrozole + Giredestrant-matched Placebo + Palbociclib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"conditions":["Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer"],"enrollment":{"count":992,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Giredestrant","otherNames":["GDC-9545","RO7197597","RG6171"],"type":"DRUG"},{"name":"Giredestrant-matched Placebo","otherNames":[],"type":"DRUG"},{"name":"Letrozole","otherNames":[],"type":"DRUG"},{"name":"Letrozole-matched Placebo","otherNames":[],"type":"DRUG"},{"name":"Palbociclib","otherNames":[],"type":"DRUG"},{"name":"LHRH Agonist","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-17","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 78 months)"}],"references":[],"start_date":{"date":"2020-10-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","url":"https://clinicaltrials.gov/study/NCT04546009"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/persevera-nct04546009"}